{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:40:28Z","timestamp":1791168028805,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Preclinically, HIV protease inhibitors radiosensitize tumors with activated PI3-kinase\/Akt pathway. We determined the toxicity of nelfinavir chemoradiotherapy in borderline resectable and unresectable pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Oral nelfinavir (2 \u00d7 1,250 mg) was started 3 days before and continued throughout chemoradiotherapy to 50.4 Gy (boost, 59.4 Gy) in 12 patients. Two gemcitabine dose levels (DL) were tested (200 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and 300 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on days 1, 8, 22, and 29). Cisplatin was administered on the same days at 30 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Phospho-Akt downregulation by nelfinavir was monitored by immunoblotting in patient leukocytes. Restaging positron emission tomography (PET)\/computed tomography (CT) and CA19-9 levels served to assess response, and responding tumors were resected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At each DL, five of six patients completed chemoradiotherapy, and two of 12 patients had incomplete chemoradiotherapy because of clinical depression (DL1) and peritoneal metastasis (DL2). Grade 4 toxicities were a transaminase elevation (DL2) as a result of biliary stent occlusion and acute cholecystitis as a result of peritoneal metastasis (DL2). Stent occlusions led to dose-limiting toxicities of grade 3 liver enzyme and bilirubin elevations (two patients at DL1, one patient at DL2). Grade 3 nausea and vomiting occurred in a DL2 patient, and weight loss occurred in a DL1 patient who refused supportive feeding. Secondary complete resection was possible in six of 10 patients with complete chemoradiotherapy, including one tumor with pathologic sterilization. Partial CT responses were observed in five of 10 patients who completed chemoradiotherapy. Of nine patients assessable by PET,responses were complete in five patients and partial patients, and stable disease was observed in two patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of nelfinavir and chemoradiotherapy showed acceptable toxicity and promising activity in patients with pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2007.15.2355","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T18:23:57Z","timestamp":1211999037000},"page":"2699-2706","source":"Crossref","is-referenced-by-count":135,"title":["Phase I Trial of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer"],"prefix":"10.1200","volume":"26","author":[{"given":"Thomas B.","family":"Brunner","sequence":"first","affiliation":[{"name":"From the Departments of Radiation Oncology and Surgery, and Department of Nuclear Medicine, Friedrich-Alexander University of Erlangen-Nuremberg, Nuremberg, Germany; and Gray Institute of Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Geiger","sequence":"additional","affiliation":[{"name":"From the Departments of Radiation Oncology and Surgery, and Department of Nuclear Medicine, Friedrich-Alexander University of Erlangen-Nuremberg, Nuremberg, Germany; and Gray Institute of Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard G.","family":"Grabenbauer","sequence":"additional","affiliation":[{"name":"From the Departments of Radiation Oncology and Surgery, and Department of Nuclear Medicine, Friedrich-Alexander University of Erlangen-Nuremberg, Nuremberg, Germany; and Gray Institute of Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marga","family":"Lang-Welzenbach","sequence":"additional","affiliation":[{"name":"From the Departments of Radiation Oncology and Surgery, and Department of Nuclear Medicine, Friedrich-Alexander University of Erlangen-Nuremberg, Nuremberg, Germany; and Gray Institute of Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine S.","family":"Mantoni","sequence":"additional","affiliation":[{"name":"From the Departments of Radiation Oncology and Surgery, and Department of Nuclear Medicine, Friedrich-Alexander University of Erlangen-Nuremberg, Nuremberg, Germany; and Gray Institute of Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Cavallaro","sequence":"additional","affiliation":[{"name":"From the Departments of Radiation Oncology and Surgery, and Department of Nuclear Medicine, Friedrich-Alexander University of Erlangen-Nuremberg, Nuremberg, Germany; and Gray Institute of Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Sauer","sequence":"additional","affiliation":[{"name":"From the Departments of Radiation Oncology and Surgery, and Department of Nuclear Medicine, Friedrich-Alexander University of Erlangen-Nuremberg, Nuremberg, Germany; and Gray Institute of Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Hohenberger","sequence":"additional","affiliation":[{"name":"From the Departments of Radiation Oncology and Surgery, and Department of Nuclear Medicine, Friedrich-Alexander University of Erlangen-Nuremberg, Nuremberg, Germany; and Gray Institute of Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Gillies","family":"McKenna","sequence":"additional","affiliation":[{"name":"From the Departments of Radiation Oncology and Surgery, and Department of Nuclear Medicine, Friedrich-Alexander University of Erlangen-Nuremberg, Nuremberg, Germany; and Gray Institute of Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2551"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70245-0"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.5663"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0158"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.5.9.3172"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1593\/neo.06823"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Altomare DA, Tanno S, De Rienzo A, et al: Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 88:470,2003-476,","DOI":"10.1002\/jcb.10287"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2006.07.011"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00214-1"},{"key":"R10","unstructured":"Ng SSW, Tsao MS, Chow S, et al: Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60:5451,2000-5455,"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000715)89:2<314::AID-CNCR16>3.0.CO;2-V"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199906180-00026"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0161"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1220"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1593\/neo.07124"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03818-X"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.168.6.9168704"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-003-1036-x"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.12.018"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1007\/s10434-001-0123-4"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.02.054"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.07.002"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.860"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000225672.68852.05"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(97)89547-5"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9032-x"},{"key":"R29","unstructured":"Ohara K, Tatsuzaki H, Molotkova NG, et al: Utility of serum CA 19-9 monitoring in preoperative radiotherapy for pancreatic cancer. Hepatogastroenterology 48:859,2001-863,"},{"key":"R30","unstructured":"Golcher H, Brunner T, Grabenbauer G, et al: Preoperative chemoradiation in adenocarcinoma of the pancreas: A single centre experience advocating a new treatment strategy. Eur J Surg Oncol  [epub ahead of print on January 9, 2008]"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2005.08.007"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Chen H, Raben D, Schefter T, et al: KRAS mutation analysis in patients (pts) with locally advanced pancreatic cancer (LAPC) treated with gefitinib and chemoradiation therapy (CT-RT) in a phase I trial. J Clin Oncol 24:204s,2006,  (suppl, abstr 4106)","DOI":"10.1200\/jco.2006.24.18_suppl.4106"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1479"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3684"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.15.2355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:16:45Z","timestamp":1653495405000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.15.2355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":33,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2008,6,1]]}},"alternative-id":["10.1200\/JCO.2007.15.2355"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.15.2355","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,1]]}}}